Phio Pharma reports 2025 net loss $8.7M; PH-762 Phase 1b dose escalation complete with favorable data

Phio Pharmaceuticals Corp.

Net loss of $8.7M ($1.45 EPS) for 2025 vs $7.2M ($9.08 EPS) in 2024; R&D expenses up 27%.
Cash at Dec 31, 2025: $21.0M vs $5.4M year ago; net proceeds from 2025 financings of $20.6M extend runway into H1 2027.
PH-762 Phase 1b dose escalation trial fully enrolled (22 patients); final cohort shows favorable safety, tolerability and pathology.
FDA submission seeking guidance on next steps for PH-762 targeted for Q2 2026; patent portfolio includes 54 issued patents.
Phio entered drug substance development agreement with US manufacturer and toxicology study agreement with US lab in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.